|

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

RECRUITINGPhase 2Sponsored by Martin T. King, MD, PhD
Actively Recruiting
PhasePhase 2
SponsorMartin T. King, MD, PhD
Started2026-04-29
Est. completion2026-12-15
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
Locations4 sites

Summary

This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target remaining cancer with radiation, while avoiding areas that may no longer need extra treatment. All participants will receive standard hormone therapy and radiation therapy, along with three imaging scans, over a six-month period. The information gained from this study may help make prostate cancer radiation treatment more precise and reduce side effects for future patients.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* 18 years of age and older.
* Eastern Oncology Group Status 0 to 1.
* Histologic diagnosis of prostate cancer.
* Prior screening MRI with at least one PI-RADS4 or PI-RADS 5 lesion, obtained within 180 days of screening.
* NCCN intermediate-risk or high-risk prostate cancer (Appendix B). All patients will be staged by MRI.
* Prior PSMA PET scan with at least one focal avid lesion greater than background prostate that is concordant with a lesion on MRI, obtained within 180 days of screening.
* Intention for SBRT (36.25 Gy/5 fraction) with focal boost (up to 50 Gy) to one MRI/PET-concordant lesion34.

Exclusion Criteria:

* Prior imaging (CT, bone scan, MRI, PSMA-PET/CT) showing nodal or distant disease.
* Intention to receive treatment intensification with secondary androgen receptor signaling inhibitors or chemotherapy.
* Clinical T4 disease.
* Prior ADT.
* Prior pelvic RT.
* Prior prostate surgery, including TURP.
* International prostate symptom score \> 20.
* Prior urethral stricture.
* Prostate volume \> 80 cc on MRI.
* Hip implants that cause artifacts over the prostate gland.
* Inability to discontinue anti-coagulation for fiducial marker placement.
* Active Crohn's disease or scleroderma.

Conditions4

CancerHigh Risk Prostate CancerIntermediate Risk Prostate CancerProstate Cancer

Interventions1

Locations4 sites

Brigham and Women's Hospital
Dana Farber Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
Milford, Massachusetts, 01757
Luke Peng, MD508-488-3800lcpeng@bwh.harvard.edu
Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital
Weymouth, Massachusetts, 02190
Luke Peng508-488-3800lcpeng@bwh.harvard.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.